To contentTo navigationTo search

Implantica presents at Redeye Future of Healthcare Seminar

 | Non regulatory

Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, announces that on Thursday, March 30, at 14:45, Peter Forsell presents Implantica and it’s latest developments at Redeye’s Future of Healthcare Seminar.

The presentation will be live broadcasted in English and can be followed at: where the replay and the presentation will be available afterwards.

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB,

The information was sent for publication, through the agency of the contact person set out above, on March 29, 2023, at 8:30 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that has the  potential to  create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information.



Technology Platform

Media Contact:

Implantica AG

Juanita Eberhart

VP Marketing & Advocacy


  • IMPLANTICA_STILL_LIFE_202098471.jpg
  • logo_transparent_1 (8).png